Back To: Home : Featured Technology : PCR/qPCR

CLICK HERE FOR WHAT'S NEW IN:
 

Sosei gains 25.6-percent stake in MiNA Therapeutics
June 2017
SHARING OPTIONS:

TOKYO & LONDON—Under a recent definitive agreement, Sosei Group Corp. will make an investment in and gain an exclusive option to potentially acquire biopharmaceutical company MiNA Therapeutics. Sosei will invest £35 million into MiNA Therapeutics in return for a 25.6-percent equity share and an exclusive option to acquire further stakes and possibly the company for an additional £140 million. Should Sosei fully exercise its option, MiNA's shareholders could receive up to £240 million based on the achievement of development and regulatory milestones and royalties.
 
Sosei CEO Peter Bains commented, “We are very pleased to enter into this agreement with MiNA, which strongly supports Sosei’s vision to become a global biotechnology company and is consistent with our inorganic strategy to both accelerate Sosei’s pipeline development and to identify complementary technologies to our world-leading Heptares GPCR platform.”

Back


PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.